公开(公告)号：US20190314527A1

公开(公告)日：2019-10-17

申请号：US16442168

申请日：2019-06-14

Applicant: ModernaTX, Inc.

Inventor： Antonin DE FOUGEROLLES ,  Jason P. SCHRUM ,  Justin GUILD

IPC: A61K48/00 ,  C12N15/85 ,  C07K14/62 ,  C07K14/47 ,  A61K38/19 ,  A61K38/18 ,  A61K9/51 ,  C12P21/00 ,  A61K47/54 ,  A61K9/14 ,  C07K16/00 ,  C07K14/515 ,  A61K38/48 ,  A61K38/21 ,  A61K38/17 ,  C12N9/64 ,  C07H21/02 ,  C07K14/435 ,  C07K14/475 ,  C07K14/495 ,  C07K14/525 ,  C07K14/54 ,  C07K14/56 ,  C07K14/61 ,  C07K14/745 ,  C07K16/28 ,  C07K16/40 ,  C12N9/02 ,  C12N9/12 ,  C12N9/68 ,  C12P13/04 ,  C12N15/87 ,  A61K38/45 ,  C12N9/00 ,  A61K9/127 ,  C12N15/11 ,  C12N9/24 ,  C12N9/16 ,  C07K14/005 ,  C07K14/535 ,  C07K14/505 ,  C07K14/705 ,  C12N15/52 ,  C12N9/42 ,  C12N9/10 ,  C07K14/485 ,  C12N9/88 ,  A61K31/7115

Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

公开(公告)号：US20190290742A1

公开(公告)日：2019-09-26

申请号：US16152945

申请日：2018-10-05

Applicant: ModernaTX, Inc.

Inventor： Tirtha CHAKRABORTY ,  Stephane BANCEL ,  Stephen G. HOGE ,  Atanu ROY ,  Antonin DE FOUGEROLLES ,  Noubar B. AFEYAN

IPC: A61K39/00 ,  C12N15/67

Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.

公开(公告)号：US20180125937A1

公开(公告)日：2018-05-10

申请号：US15621693

申请日：2017-06-13

Applicant: ModernaTX, Inc.

Inventor： Antonin DE FOUGEROLLES ,  Kristy M. WOOD ,  Sayda M. ELBASHIR ,  Noubar B. AFEYAN ,  Pedro VALENCIA ,  Jason P. SCHRUM

IPC: A61K38/19 ,  C12N15/00 ,  C12P21/00 ,  A61K9/14 ,  A61K9/127 ,  A61K38/48 ,  A61K48/00 ,  C07K14/535 ,  A61K31/7105 ,  A61K9/16 ,  A61K9/00 ,  A61K31/7088 ,  C07K2/00 ,  C12N15/117 ,  C12N15/88

CPC classification number: A61K38/193 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/0048 ,  A61K9/1271 ,  A61K9/1272 ,  A61K9/14 ,  A61K9/16 ,  A61K9/1647 ,  A61K31/7088 ,  A61K31/7105 ,  A61K38/4833 ,  A61K48/00 ,  A61K48/0033 ,  A61K48/0041 ,  A61K48/005 ,  A61K48/0066 ,  C07K2/00 ,  C07K14/535 ,  C12N15/00 ,  C12N15/117 ,  C12N15/88 ,  C12P21/00

Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.

公开(公告)号：US20250074962A1

公开(公告)日：2025-03-06

申请号：US18592122

申请日：2024-02-29

Applicant: ModernaTX, Inc.

Inventor： Antonin DE FOUGEROLLES ,  Justin GUILD

IPC: C07K14/535 ,  A61K9/00 ,  A61K9/127 ,  A61K9/14 ,  A61K9/50 ,  A61K31/7088 ,  A61K31/7115 ,  A61K38/17 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  A61K38/36 ,  A61K38/44 ,  A61K38/48 ,  A61K39/395 ,  A61K47/10 ,  A61K47/60 ,  A61K48/00 ,  C07K14/47 ,  C07K14/475 ,  C07K14/505 ,  C07K14/525 ,  C07K14/56 ,  C07K14/565 ,  C07K14/745 ,  C07K14/75 ,  C07K16/28 ,  C07K16/32 ,  C07K19/00 ,  C12N9/02 ,  C12N9/64 ,  C12N15/85 ,  C12N15/88

Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

公开(公告)号：US20240327476A1

公开(公告)日：2024-10-03

申请号：US18634220

申请日：2024-04-12

Applicant: ModernaTx, Inc.

Inventor： Antonin DE FOUGEROLLES ,  Justin GUILD

IPC: C07K14/47 ,  A61K9/00 ,  A61K9/127 ,  A61K9/14 ,  A61K9/50 ,  A61K9/51 ,  A61K31/7088 ,  A61K31/7115 ,  A61K38/00 ,  A61K38/17 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  A61K38/36 ,  A61K38/44 ,  A61K38/45 ,  A61K38/48 ,  A61K39/395 ,  A61K47/10 ,  A61K47/34 ,  A61K47/54 ,  A61K48/00 ,  C07K14/005 ,  C07K14/435 ,  C07K14/475 ,  C07K14/485 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K14/75 ,  C07K16/00 ,  C07K16/28 ,  C07K16/32 ,  C07K19/00 ,  C12N9/00 ,  C12N9/02 ,  C12N9/10 ,  C12N9/16 ,  C12N9/24 ,  C12N9/42 ,  C12N9/64 ,  C12N9/88 ,  C12N15/11 ,  C12N15/52 ,  C12N15/67 ,  C12N15/85 ,  C12N15/87 ,  C12N15/88 ,  C12P13/04 ,  C12P21/00

CPC classification number: C07K14/47 ,  A61K9/1271 ,  A61K9/1272 ,  A61K9/1277 ,  A61K9/14 ,  A61K9/145 ,  A61K9/5031 ,  A61K9/5123 ,  A61K9/5146 ,  A61K9/5153 ,  A61K31/7088 ,  A61K31/7115 ,  A61K38/17 ,  A61K38/1767 ,  A61K38/177 ,  A61K38/1816 ,  A61K38/1866 ,  A61K38/1891 ,  A61K38/191 ,  A61K38/193 ,  A61K38/212 ,  A61K38/215 ,  A61K38/36 ,  A61K38/363 ,  A61K38/44 ,  A61K38/45 ,  A61K38/4833 ,  A61K38/4846 ,  A61K39/3955 ,  A61K47/10 ,  A61K47/34 ,  A61K47/54 ,  A61K47/542 ,  A61K47/543 ,  A61K48/0033 ,  A61K48/005 ,  A61K48/0066 ,  A61K48/0075 ,  C07K14/005 ,  C07K14/435 ,  C07K14/4705 ,  C07K14/4713 ,  C07K14/485 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K14/75 ,  C07K16/00 ,  C07K16/2887 ,  C07K16/32 ,  C07K19/00 ,  C12N9/0069 ,  C12N9/1051 ,  C12N9/16 ,  C12N9/2402 ,  C12N9/2445 ,  C12N9/644 ,  C12N9/6451 ,  C12N9/88 ,  C12N9/93 ,  C12N15/11 ,  C12N15/52 ,  C12N15/67 ,  C12N15/85 ,  C12N15/87 ,  C12N15/88 ,  C12P13/04 ,  C12P21/00 ,  C12P21/005 ,  C12Y113/12007 ,  C12Y304/21005 ,  C12Y603/02019 ,  A61K9/0019 ,  A61K38/00 ,  A61K48/00 ,  C07K14/475 ,  C12N2840/00 ,  C12N2840/85 ,  C12Y304/21022

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US20240165267A1

公开(公告)日：2024-05-23

申请号：US18058656

申请日：2022-11-23

Applicant: ModernaTX, Inc.

Inventor： Atanu ROY ,  Christopher R. CONLEE ,  Antonin DE FOUGEROLLES ,  Andrew W. FRALEY

IPC: A61K48/00 ,  A61K38/18 ,  A61K38/19 ,  C07H19/10 ,  C07H21/00 ,  C12N15/11 ,  C12P19/34 ,  C12P21/00

CPC classification number: A61K48/0066 ,  A61K38/1816 ,  A61K38/193 ,  C07H19/10 ,  C07H21/00 ,  C12N15/11 ,  C12P19/34 ,  C12P21/00 ,  C12P21/005 ,  A61K48/00 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/335 ,  C12N2310/336 ,  C12N2320/30

Abstract: The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.

公开(公告)号：US20240123035A1

公开(公告)日：2024-04-18

申请号：US18177455

申请日：2023-03-02

Applicant: ModernaTX, Inc.

Inventor： Antonin DE FOUGEROLLES ,  Kristy M. Wood ,  Sayda M. ELBASHIR ,  Noubar B. Afeyan ,  Pedro VALENCIA ,  Jason P. SCHRUM

IPC: A61K38/19 ,  A61K9/00 ,  A61K9/127 ,  A61K9/14 ,  A61K9/16 ,  A61K31/7088 ,  A61K31/7105 ,  A61K38/48 ,  A61K48/00 ,  C07K2/00 ,  C07K14/535 ,  C12N15/00 ,  C12N15/117 ,  C12N15/88 ,  C12P21/00

CPC classification number: A61K38/193 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/0048 ,  A61K9/1271 ,  A61K9/1272 ,  A61K9/14 ,  A61K9/16 ,  A61K9/1647 ,  A61K31/7088 ,  A61K31/7105 ,  A61K38/4833 ,  A61K48/00 ,  A61K48/0033 ,  A61K48/0041 ,  A61K48/005 ,  A61K48/0066 ,  C07K2/00 ,  C07K14/535 ,  C12N15/00 ,  C12N15/117 ,  C12N15/88 ,  C12P21/00

Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.

公开(公告)号：US20220273555A1

公开(公告)日：2022-09-01

申请号：US16860121

申请日：2020-04-28

Applicant: ModernaTX, Inc.

Inventor： Stephane BANCEL ,  Tirtha CHAKRABORTY ,  Antonin DE FOUGEROLLES ,  Sayda M. ELBASHIR ,  Matthias JOHN ,  Atanu ROY ,  Susan WHORISKEY ,  Kristy M. WOOD ,  Paul HATALA ,  Jason P. SCHRUM ,  Kenechi EJEBE ,  Jeff Lynn ELLSWORTH ,  Justin GUILD

IPC: A61K9/00 ,  C12N15/67

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US20200155706A1

公开(公告)日：2020-05-21

申请号：US16577734

申请日：2019-09-20

Applicant: ModernaTX, Inc.

Inventor： Antonin DE FOUGEROLLES ,  Justin GUILD

IPC: A61K48/00 ,  C12P21/00 ,  C07K16/00 ,  C07K14/515 ,  A61K38/48 ,  A61K38/21 ,  A61K38/19 ,  A61K38/18 ,  A61K9/51 ,  A61K9/14 ,  A61K47/54 ,  C12N9/64 ,  C12N9/68 ,  C12N9/12 ,  C12N9/02 ,  C07K16/40 ,  C07K16/28 ,  C07K14/745 ,  C07K14/61 ,  C07K14/56 ,  C07K14/54 ,  C07K14/525 ,  C07K14/495 ,  C07K14/475 ,  C07K14/47 ,  C07K14/435 ,  C07H21/02 ,  C07K14/485 ,  A61K38/17 ,  C12N15/52 ,  C12N9/24 ,  C12N9/16 ,  C07K14/005 ,  A61K38/45 ,  C12P13/04 ,  C12N15/87 ,  C12N9/42 ,  C12N9/00 ,  C12N9/10 ,  C07K14/535 ,  C07K14/505 ,  C07K14/705 ,  C12N15/11 ,  A61K9/127 ,  C12N9/88 ,  A61K31/7115 ,  C07K14/62 ,  C12N15/85

Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

公开(公告)号：US20200017565A1

公开(公告)日：2020-01-16

申请号：US16438978

申请日：2019-06-12

Applicant: ModernaTX, Inc.

Inventor： Antonin DE FOUGEROLLES ,  Justin GUILD

IPC: C07K14/535 ,  A61K47/54 ,  A61K48/00 ,  C12N15/88 ,  A61K9/127 ,  A61K9/50 ,  C07K14/47 ,  A61K31/7088 ,  C07K19/00 ,  C12N15/85 ,  A61K38/18 ,  A61K38/19 ,  A61K38/48 ,  A61K9/14 ,  A61K38/17 ,  A61K47/10 ,  A61K38/21 ,  A61K38/36 ,  A61K38/44 ,  A61K39/395 ,  C07K14/475 ,  C07K14/505 ,  C07K14/525 ,  C07K14/56 ,  C07K14/565 ,  C07K14/745 ,  C07K14/75 ,  C07K16/28 ,  C07K16/32 ,  C12N9/02 ,  C12N9/64

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.